Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. (2019)

First Author: Mofenson LM
Attributed to:  Centre for Drug Safety Science (CDSS) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/jia2.25352

PubMed Identifier: 31298496

Publication URI: http://europepmc.org/abstract/MED/31298496

Type: Journal Article/Review

Volume: 22

Parent Publication: Journal of the International AIDS Society

Issue: 7

ISSN: 1758-2652